1. Introduction {#s0005}
===============

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia with typical chromosomal translocation t(15; 17), which results in the formation of leukemogenic chimerical gene *PML*--*RARα*. The PML--RARα oncoproteins exert a dominant-negative effect on their normal counterparts, PML and RARα, which are involved in the regulation of the physiological processes of myeloid differentiation, apoptosis and DNA replication/repair ([@bb0040], [@bb0085], [@bb0105], [@bb0125], [@bb0180], [@bb0235], [@bb0245], [@bb0280]). Bleeding tendency caused by either hypofibrinogenemia or disseminated intravascular coagulation (DIC) and accumulation of promyelocytes in the bone marrow (BM) are common clinical features ([@bb0040], [@bb0085], [@bb0080], [@bb0230]).

The revolutionary introduction of all-trans retinoic acid (ATRA) has significantly changed the treatment paradigm of APL ([@bb0125], [@bb0165], [@bb0200]). The terminal differentiation of APL cells upon effect of ATRA, instead of cytolysis by conventional chemotherapy, ameliorates the coagulopathy of the disease and increases the complete remission (CR) rate of induction ([@bb0230], [@bb0165], [@bb0200], [@bb0275]). Currently, ATRA based treatment has become the standard care of the APL which significantly prolongs disease-free survival (DFS) and overall survival (OS) ([@bb0105], [@bb0010], [@bb0075], [@bb0095], [@bb0100], [@bb0120], [@bb0220]). Since the 1990s, arsenic trioxide (ATO) has yielded breakthroughs in treating both relapsed and newly diagnosed APL patients and has been shown to induce differentiation and apoptosis of APL cells. Mechanistic exploration proved that ATRA and ATO exert direct effects on distinct functional domains of the same PML--RARα oncoprotein. While ATRA targets the ligand-binding domain (LBD) of RARα moiety, arsenic binds to adjacent cysteine residues located within the RING, B Boxes and coiled coil (RBCC) domain of PML. Both agents induce degradation of the fusion protein. Interestingly, arsenic binding results in an oligomerization of PML--RARα and increases its interaction with the small ubiquitin-like protein modifier (SUMO)-conjugating enzyme UBC9, leading to enhance SUMOylation. The sumoylated fusion protein on its turn recruits the ubiquitin E3 ligase RNF4 and undergoes proteasome-mediated degradation ([@bb0045], [@bb0140], [@bb0190], [@bb0255], [@bb0270]). In addition, leukemia-initiating cells (LICs), which are responsible for relapse of leukemia, could be cleared by ATRA/ATO based treatment in murine models, providing further rationale of combined use of the two agents ([@bb0005], [@bb0130], [@bb0170], [@bb0175], [@bb0265]). The potential synergic effect of ATRA and ATO owing to different modes of action represents thus a strong impetus for the trial of combination of ATRA and ATO in the newly diagnosed APL. Indeed, ATRA/ATO combination as first line induction therapy with chemotherapy as consolidation has not only brought a shortened time to achieve CR but more importantly reduced disease burden and substantially enhanced survival as compared to patients treated with each of the two agents in an initial randomized trial at the Shanghai Institute of Hematology (SIH) ([@bb0120], [@bb0220]). Then in the extended arm of ATRA/ATO/chemotherapy combination for 85 APL patients, remarkable 5-year event-free survival (EFS) and OS rates of 89.2% ± 3.4% and 91.7% ± 3.0%, respectively, were achieved ([@bb0120]). The results were then confirmed by several hematology/oncology centers in Western countries. [@bb0155] recently reported that by using ATRA and ATO alone in the treatment of newly diagnosed low-to-intermediate-risk patients, the CR rate could be as high as 100% with a 2 year EFS of 97% ([@bb0155]).

Laboratory and clinical evidence strongly suggests that mutations of LBD of RARα and B box2 of PML in *PML*--*RARα* are responsible for resistance to ATRA and ATO, respectively ([@bb0140], [@bb0255], [@bb0115]). However, these mutations generally occur at the time of relapse. Previously we and others observed that at disease presentation, some other molecular events could co-exist with *PML*--*RARα* such as mutations of *NRAS*, *KRAS*, FMS-like tyrosine kinase 3 \[with internal tandem duplication (*FLT3*-ITD) or *FLT3* point mutations (*FLT3*-TKD)\] and *JAK1*. In APL patients treated with ATRA and chemotherapy, these mutations might exert potential impact on the biological behavior, clinical manifestation and treatment outcome ([@bb0035], [@bb0195], [@bb0225]). More recently, when new genetic markers such as *DNMT3A* and *IDH1*/*2* were used for mutation screening in APL and genomic data of some APL cases were available ([@bb0225], [@bb0240]), it was revealed that still other gene mutations could exist and be related to disease outcome.

In this study, we have investigated the gene mutational status of APL in addition to *PML*--*RARα* to clarify their potential biological and clinical impact among patients treated with ATRA/ATO based protocol in an attempt to further improve the stratification system of APL.

2. Methods {#s0010}
==========

2.1. Patients and Treatment {#s0015}
---------------------------

A total of 535 newly diagnosed APL patients were enrolled from February 2001 to February 2014, whose samples were sent to SIH for molecular assessment. The training group consisted of 266 patients who were treated by Shanghai APL regimen with ATRA/ATO based protocol in SIH affiliated centers ([@bb0120]), during February 2001 and March 2008. The validation group consisted of 269 patients in three multi-center clinical trials from SIH, Zhejiang Institute of Hematology (ZIH) and Peking University Institute of Hematology ([@bb0285]). All cases in these three groups were treated with the same ATRA/ATO based protocol as in the training group. The detailed treatment protocols are seen in Supplementary Fig. 1.

The diagnosis of the disease was established according to the nomenclature of WHO for leukemia. Cytogenetic and molecular examinations of t(15;17) and/or *PML*--*RARα* were performed as previously described. Based on the levels of initial WBC and platelets by Sanz risk stratification, the patients could be classified into 3 groups: high-risk, WBC above 10 × 10^9^/L; low-risk, WBC below 10 × 10^9^/L and platelet more than 40 × 10^9^/L, and intermediate-risk, all the remaining cases, respectively ([@bb0205]).

This study was approved by the Institutional Review Board (IRB) of all participating hospitals. All patients were given informed consent for both treatment and cryopreservation of bone marrow (BM) and peripheral blood (PB) according to the Declaration of Helsinki.

2.2. Molecular Genetic Analysis {#s0020}
-------------------------------

Genomic DNA and total RNA were extracted as previously reported. Regular RT-PCR of 3 distinct \[long (L), short (S), and variant (V)\] types of *PML*--*RARα* transcripts were analyzed as described previously ([@bb0090]).

Gene mutational status analysis was performed in all patients. A series of gene markers were chosen based on our previous study on a group of 388 APL patients ([@bb0225]) and on detailed analysis of the genomic data in the literature ([@bb0030]). Mutations including *FLT3*-ITD or -TKD, *N*-*RAS*, *C*-*KIT*, *NPM1*, *CEPBA*, *WT1*, *ASXL1*, *DNMT3A*, *MLL*, *IDH1*, *IDH2* and *TET2* genes were assessed by distinct approaches. A chip-based matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI--TOF MS) analysis system (iPLEXTM, Sequenom, San Diego, CA, USA) was used to analyze the mutational status of *FLT3*-TKD, *N*-*RAS*, *NPM1*, and whole gene sequencing was applied to investigate the mutations of *FLT3*-ITD, *C*-*KIT*, *CEPBA*, *WT1*, *ASXL1*, *DNMT3A*, *IDH1*, *IDH2* and *TET2* genes ([@bb0225], [@bb0015], [@bb0025], [@bb0070]). Six *MLL*-related common fusion genes including *MLL*-*AF9*, *MLL*-*AF10*, *MLL*-*AF6*, *MLL*-*ELL*, *MLL*-*ENL* and *MLL*-*AF17* were detected via a multiplex RT-PCR strategy ([@bb0090]). The mutational status of *MLL*-PTD was determined by RT-PCR technique.

A RT-PCR was performed to detect mutations of *PML*--*RARα* in relapsed patients. 1 μg of total RNA was reversely transcribed to cDNA using M-MLV reverse transcriptase kit (Invitrogen). Then r-Taq polymerase kit (Takara) was used to perform PCR and amplified PCR fragments were subjected to Sanger sequencing. Since recent studies had revealed the enrichment of *PML* mutations in the RBCC B2 domain and of *RARα* mutations in LBD domain ([@bb0115]), the primers for PCR amplification of these two domains were designed as follows: PML-RBCC-Forward 5′-CAGATTGTGGATGCGCAGGC and PML-RBCC-Reverse 5′-CAGCCGACTGGCCATCTCCT;RARA-LBD-Forward5′-GAAGAAGAAGGAGGTGCCCAandRARA-LBD-Reverse 5′-CATCTTCAGCGTGATCACCC. The PCR was carried out in the reaction mixtures according to the provided protocol of rTaq and amplification was under the following conditions: 95 °C for 5 min of one cycle, followed by 35 cycles of 30 s at 95 °C, 40 s at 58 °C and 50 s at 72 °C, and a final stage of 5 min at 72 °C. The resulting data of Sanger sequencing were analyzed by software Chromas lite (Technelysium).

2.3. Statistical Analyses {#s0025}
-------------------------

Fisher\'s exact P test was used to compare the difference of CR rates which was defined according to the criteria of International Working Group ([@bb0060]). One way Anova test was used to compare the age, WBC count and BM blasts at diagnosis in different groups. OS was measured from the date of disease diagnosis to death (failure) or alive at the last follow-up (censored). DFS was defined as the duration from the documentation of CR to treatment failure such as relapse, refractory disease, death, or alive in CR at the last follow-up (censored) ([@bb0060], [@bb0065]). Kaplan--Meier and hazard ratio analyses were used to calculate and compare the OS and DFS, respectively. Cox model was used for the multivariate analysis of associations of survival and potential prognostic factors. A limited backward selection procedure was used to exclude redundant variates ([@bb0110]). The above statistical procedures were all performed with the SPSS statistical software package, version 16.0.

3. Results {#s0035}
==========

3.1. Characteristics of Patients {#s0040}
--------------------------------

The demographic data of 535 APL patients in both training (266 cases) and validation (269 cases) groups were depicted in [Table 1](#t0005){ref-type="table"}. The clinical variables including age, gender, and median WBC count were similar between the two cohorts. The validation group seemed to contain more *FLT3* mutation cases and high-risk patients. However, the frequency of ITD and TKD in training and validation groups (P = 0.641) was similar.

3.2. Molecular Aspects of the Patients {#s0045}
--------------------------------------

In the pooled data of 535 patients, *FLT3*-ITD or -TKD (84/531, 15.8%), *N*-*RAS* (23/509, 4.5%) and *WT*-*1* (24/515, 4.7%) mutations were identified as the three most common additional gene mutations. Notably, mutations of epigenetic modifier genes (EMGs), such as *DNMT3A* (0.3%), *TET2* (4.5%), *IDH1* (0.4%), *IDH2* (0.2%) and *ASXL1* (1.6%), could co-exist with *PML*--*RARα* fusion, whereas no PTD mutation or fusion of *MLL* was noted in any cases, suggesting a mutual exclusivity between *MLL* abnormalities and the *PML*--*RARα* characteristic of APL. Put together, 35 (6.5%) out of 535 patients harbored EMG mutations.

As shown in [Table 2](#t0010){ref-type="table"}, the *FLT3*-ITD/TKD mutations and *N*-*RAS* mutations were associated with a phenotype of high WBC count (P \< 0.001 and P = 0.001, respectively), whereas *FLT3* mutations also showed a male tendency (P = 0.012). When the possible relationships between distinct gene mutations were analyzed, 164 patients (30.7%) carried at least one of the above mentioned mutations, while 18 patients (3.4%) carried double or triple additional mutations. EMG mutations tended to co-exist with other mutations. Among 18 patients with two or three gene mutations, 11 (61.1%) cases contained EMG abnormalities (P \< 0.001).

The correlations between additional mutations and clinical risk groups were addressed ([Fig. 1](#f0005){ref-type="fig"}). Of note, over half of patients in high-risk group carried these mutations (66/131, 50.4%), significantly higher than those in the intermediate- (62/248, 25.0%) and low-risk group (36/156, 23.1%) (P \< 0.001, respectively). High-risk patients tended to carry more signaling molecule gene mutations, such as *FLT3* (P \< 0.001), as compared with low-intermediate risk ones. The distributions of other mutations were similar among different groups as shown in [Table 2](#t0010){ref-type="table"}.

3.3. Treatment Response {#s0050}
-----------------------

In the training group, 251 out of 266 (94.4%) APL cases treated with ATRA/ATO combination therapy in SIH-related centers during 2001 to 2008 achieved CR. Among 269 cases treated with the same regimen but in a multi-center trial setting as validation group ([Table 3](#t0015){ref-type="table"}), 253 out of 269 patients (94.1%) reached to CR. In univariate analysis for potential prognostic factor on induction outcome, Sanz low-risk patients could achieve a higher CR rate than the intermediate-high-risk patients in both training and validation groups (P = 0.007 for both training and validation groups, [Table 3](#t0015){ref-type="table"}). No adverse effects of *FLT3*-ITD/TKD, *N*-*RAS*, *WT1* and EMG mutations were observed on CR induction.

A multivariate analysis was performed in 467 pooled patients of training and validation groups, who were with complete molecular results of *FLT3*, *N*-*RAS*, *WT1*, and all EMG mutations. Sanz risk stratification (P = 0.001, OR 2.815 \[1.566--5.059\]) and *WT1* (P = 0.048, OR 0.297 \[0.089--0.988\]) were correlated with the results of CR induction. The complete set of covariates that entered into multivariate model was shown in [Table 5](#t0025){ref-type="table"}.

Early death (ED) constituted the main reason of induction failure. Among the total 31 ED cases, the main causes of death were intracranial hemorrhage (22 patients), followed by differentiation syndrome (6 patients) and cerebral/cardiac infarction (3 patients).

3.4. Survival Analysis {#s0055}
----------------------

In univariate analysis, Sanz risk stratification was strongly associated with the prognosis in terms of OS (HR = 0.402, 95% CI 0.223--0.725; P = 0.002) in training group, which was confirmed by validation group OS (HR = 0.323, 95% CI 0.165--0.632; P = 0.001) ([Fig. 2](#f0010){ref-type="fig"}A--D). Interestingly, EMG mutations suggested an inferior treatment outcome in terms of OS (HR = 3.335, 95% CI 1.139--9.759; P = 0.028) and DFS (HR = 6.761, 95% CI 2.179--20.984; P = 0.001) in training group, with a median follow-up of 84 months ([Fig. 3](#f0015){ref-type="fig"}A and B). We then addressed the survival impact of clinical and molecular factors in 269 cases of validation group, with a median follow-up of 38 months. Although EMG mutations did not have a statistically significant effect on OS (P = 0.119, [Fig. 3](#f0015){ref-type="fig"}C), they profoundly affected the DFS (HR = 4.026, 95% CI 1.089--14.878; P = 0.037, [Fig. 3](#f0015){ref-type="fig"}D). No prognostic effects of *FLT3*-ITD/TKD on OS and DFS were observed in either training or validation groups ([Fig. 4](#f0020){ref-type="fig"}A--D). Similarly, no significant effects of *WT1* and *NRAS* mutations were noted on treatment outcomes in the two groups (Supplementary Table 1). Although double or triple mutations suggested poor prognosis in training group, they were not proved in validation group (Supplementary Fig. 2).

In the pooled set of 535 patients, the median follow-up time was 48 months. The estimated 5-year survival rates for different clinical and gene mutational status were shown in [Table 4](#t0020){ref-type="table"}. In the multivariate analysis of 467 patients, the independent factors indicating poor prognosis included Sanz risk stratification for OS (OR = 0.386, 95% CI 0.247--0.605, P \< 0.001) and EMG mutations for OS (OR = 2.721, 95% CI 1.212--6.105, P = 0.015) and DFS (OR = 4.702, 95% CI 1.895--11.671, P = 0.001), respectively ([Table 5](#t0025){ref-type="table"}).

3.5. Point Mutations in Coding Sequences of *PML*--*RARα* in Relapsed Patients With EMG Mutations {#s0060}
-------------------------------------------------------------------------------------------------

To investigate the possible association of point mutations in *PML*--*RARα* to ATRA/ATO sensitivity, we examined the coding sequences of *PML*--*RARα* in five pairs of samples at initial diagnosis and the first relapse in patients with EMG mutations. *PML* mutation was identified in one patient in the B2 box (L218H) of the RBCC domain at relapse (Supplementary Fig. 3), which was associated with drug resistance and cause of death. No mutations were identified in the *RARα* portion of the fusion transcripts in all five pairs of samples. In the four patients without any mutations of *PML*--*RARα*, three were still sensitive to ATRA/ATO while the other case with a *DNMT3A* mutation at initial diagnosis developed a CNS leukemia and died soon.

4. Discussion {#s0065}
=============

ATRA plus chemotherapy (anthracyclines alone or with Ara-C) has been used as routine practice for treatment of APL in hematology/oncology centers worldwide ([@bb0085], [@bb0010], [@bb0075], [@bb0100], [@bb0155], [@bb0205]). ATO was tested in re-induction in relapsed patients with a CR rate more than 80% ([@bb0230], [@bb0220], [@bb0215]). We initially proposed simultaneous use of ATRA and ATO in newly diagnosed patients based on several lines of evidence. First, ATO and ATRA target, respectively, the N- and C-terminals of PML--RARα and modulate key pathways involved in apoptosis/differentiation. Hence a combined use of the two agents may bring synergistic effect ([@bb0245], [@bb0255]). Second, evidence from pre-clinical study showed that ATRA/ATO combination could significantly reduce the tumor burden or even eliminate the disease in experimental APL animal models ([@bb0150]). Third, transcriptome/proteome analysis of APL cells upon the joint effect of the two agents showed enhanced induction of differentiation/apoptosis associated pathways in the absence of obvious induction of pathways related to cell toxicity ([@bb0260]). Fourth, the ATO-induced second or third CR in patients relapsed after treatment with ATRA/chemotherapy usually didn\'t last long.

Indeed, with the ATRA/ATO combination therapy, the clinical outcome of APL has dramatically changed and the disease has been transformed from highly fatal to highly curable in a great majority of patients ([@bb0040], [@bb0105], [@bb0125], [@bb0180], [@bb0230], [@bb0120], [@bb0220], [@bb0255], [@bb0270], [@bb0285], [@bb0130], [@bb0265], [@bb0155], [@bb0215]). Recent evidence from Huang et al. also proved that ATRA in combination of an oral arsenic compound, As~4~S~4~, is as effective as ATRA/ATO ([@bb0285]). A comparison of the results between a historic control group of 97 cases treated with ATO as rescue for relapse after ATRA/chemotherapy regimen (ATRA → ATO group) yielded an outcome significantly inferior to that achieved by simultaneous use of the two medicines in 535 cases in this series (ATRA/ATO group). With a median follow-up time of 60 months, the 5 year OS and DFS rates were respectively 68.3 ± 4.8% and 76.4 ± 5.4% in ATRA → ATO group as compared to 89.9% ± 1.4% and 92.9 ± 1.3% in ATRA/ATO group (P \< 0.001 for both OS and DFS, Supplementary Fig. 4A, B). However, APL is not a homogenous disease and can be stratified into low-, intermediate- and high-risk groups according to clinical parameters, such as WBC and platelet ([@bb0200], [@bb0205]). Even with ATRA/ATO treatment, a sizable portion of high-risk patients (17.6% in this study) still experienced difficult induction intercourse, disease recurrence and short survival. A low percentage of cases in low- and intermediate-risk groups still got relapse (3.2% and 5.2%, respectively). Therefore, it is important to identify more sensitive markers to have a better stratification system for APL ([@bb0200]).

Adverse effects of gene mutations additional to *PML*--*RARα* fusion, especially *FLT3*-ITD/TKD, on the prognosis of APL drew attentions in recent years; however, the results were controversial among different research groups ([@bb0020]). Previous prognostic studies had often been limited by the diversity of the treatment protocols, and the absence of ATO in the front-line treatment ([@bb0010], [@bb0220], [@bb0265], [@bb0155], [@bb0285], [@bb0160], [@bb0185]). In this work, we examined the possible effects of additional gene mutations in two large cohorts of APL patients with homogenous ATRA/ATO treatment. It was found that a number of gene point mutations or insertion events could occur in APL in the presence of fusion gene, with the mutations of signaling molecules being the most frequent ones. Mutations of *FLT3* and *N*-*RAS* were significantly correlated with high initial WBC count at diagnosis. With regard to risk groups, we discovered that nearly half of the high-risk patients (50.4%) carried additional mutations, mostly those of *FLT3* and *N*-*RAS*, which could reflect the molecular complexity in this group as compared with intermediate- and low-risk ones. A large body of evidence suggests that molecular markers are not only correlated to clinical features at disease onset, but also potentially associated with drug response and prognosis of AML. Nevertheless, the impact of certain biomarkers can be deeply affected by treatment factors. To this end, it may be noteworthy that although *FLT3*-ITD or -TKD mutations exerted negative impact on the OS and DFS in historic control of 97 patients in ATRA → ATO group (Supplementary Fig. 5A, B), the introduction of ATO into the first line treatment in ATRA/ATO group abrogated this negative impact in both training and validation groups ([Fig. 4](#f0020){ref-type="fig"}A--D). In contrast, the adverse effects of EMG abnormalities were not influenced by ATRA/ATO combination, especially for DFS. The mechanism underlying negative prognostic effect of EMG mutations remains unclear. It is assumed that several factors may contribute to its effect. First, by altering DNA methylation and/or histone modification patterns, EMG mutations on their own can profoundly affect the gene expression profiles in favor of the acquisition of growth and survival advantages of hematopoietic stem/progenitor cells ([@bb0225], [@bb0135], [@bb0145], [@bb0250]) and some of them have been shown to be leukemogenic in animal models ([@bb0050], [@bb0055]). Hence, the presence of these mutations could render APL stem/progenitor cells even more resistant to current therapies. Second, EMG mutations tended to co-exist with other mutations (in this series of APL, 11/35, P \< 0.001), which may add complexities to leukemogenesis. Although the negative effect of multiple mutations could not be proved in validation group, longer follow-up is warranted. Third, gene mutations associated with epigenetic regulations are involved in DNA repair ([@bb0210]), whose abnormalities could make APL stem/progenitor cells prone to mutational events especially under the selective pressure of ATRA/ATO, such as those of *PML*--*RARα* gene, which potentially leads to the relapse of the disease. Of course, more clinical and experimental evidence should be accumulated to support the above view points.

Sanz risk stratification is still useful in identifying patient cohorts with different treatment outcomes, especially in terms of early CR induction, which was the only independent factor in multivariate analysis in this study. In both training and validation groups, 78/78 (100%) and 78/78 (100%) patients of low-risk groups achieved CR, and ED tended to occur in the high-risk group. In addition, Sanz risk stratification was significant in predicting OS ([Fig. 2](#f0010){ref-type="fig"}, [Table 5](#t0025){ref-type="table"}). However, the effect of Sanz\'s score in predicting the recurrence of the disease was not strong. Therefore, albeit the introduction of ATRA/ATO into front-line treatment, risk factors adapted treatment strategy may be reconsidered. Given the excellent results of low-risk patients (5 year OS and DFS of 99.2 ± 0.8 and 96.3 ± 1.7%, respectively), less toxic regimens such as ATRA/ATO without chemotherapy may be used as already reported by [@bb0155]. As for intermediate-risk patients, whose prognosis was relatively poor compared to low-risk ones in our series, randomized clinical trial is warranted to compare the results of ATRA/ATO with chemotherapy and those of ATRA/ATO without chemotherapy. New consolidation strategies containing ATO, Ara-C and other potential new agents might be the choice for high-risk group. Of note, cases with EMG mutations may need further enhanced therapy such as high dose anthracyclines and regulatory agents for DNA methylation and/or histone modification to improve their clinical outcome.

In conclusion, in an era of ATRA/ATO treatment, both molecular markers, EMG in particular, and clinical parameter based stratification systems should be used as potential prognostic factors for APL. More refined protocols considering the complexity of molecular pathogenesis of APL such as additional mutations should be designed, especially in high- and intermediate-risk groups, in an attempt to cure all APL patients.
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![Kaplan--Meier curves for overall survival (OS) and disease free survival (DFS) according to EMG mutational status in univariate analysis. (A, B) OS and DFS of patients with EMG mutations in training group. (C, D) OS and DFS of patients with EMG mutations in validation group.](gr3){#f0015}

![Kaplan--Meier curves for overall survival (OS) and disease free survival (DFS) according to *FLT3* mutational status in univariate analysis. (A, B) OS and DFS of patients with *FLT3* mutations in training group. (C, D) OS and DFS of patients with *FLT3* mutations in validation group.](gr4){#f0020}

###### 

Clinical characteristics of the patients.

                         Training group (n = 266)   Validation group (n = 269)
  ---------------------- -------------------------- ----------------------------
  Age (years)                                       
   Mean                  36.8 ± 16.0                39.6 ± 13.2
   Range                 14--77                     14--76
  Gender                                            
   Male                  136 (51.2)                 140 (52.0)
   Female                130 (48.8)                 129 (48.0)
  WBC count, × 10^9^/L                              
   Median                2.8                        2.5
   Range                 0.3--205.7                 0.3--122.2
  Risk stratification                               
   High                  57 (21.4)                  74 (27.5)
   Intermediate          131 (49.2)                 117 (43.5)
   Low                   78 (29.3)                  78 (20.0)
  *FLT3*                                            
   Mutated               34 (12.8)                  50 (18.9)
   ITD                   22 (64.7)                  35 (70.0)
   TKD                   12 (35.3)                  15 (30.0)
   Not mutated           232 (87.2)                 215 (81.1)
   Failed                0                          4
  *RAS*                                             
   Mutated               14 (5.4)                   9 (3.9)
   Not mutated           244 (94.6)                 242 (96.1)
   Failed                8                          18
  *WT1*                                             
   Mutated               11 (4.4)                   13 (4.9)
   Not mutated           238 (95.6)                 253 (95.1)
   Failed                17                         3
  EMG (%)                                           
   Mutated               14 (5.3)                   21 (7.8)
   Not mutated           224 (94.7)                 219 (92.2)
   Failed                28                         29

WBC, white blood cell; BM, bone marrow; and n, number of patients.

"Failed" refers to the samples without detection results due to quality problems.

EMG refers to a group of epigenetic modifier genes investigated in this work.

###### 

Gene mutations and clinical aspects.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene mutations                                       Gender\               Mean age (yrs)   Median WBC count, × 10^9^/L (range)   Sanz risk stratification                             
                                                       No. of the patients                                                                                                               
  ---------------------------------------------------- --------------------- ---------------- ------------------------------------- -------------------------- ------------------- ----- ----
  *FLT3*-ITD or -TKD (Failed = 4)                      Mutated               54               30                                    37.2 ± 15.3                8.85 (0.5--205.7)   39    45

  Not mutated                                          220                   227              38.3 ± 14.5                           2.3 (0.3--122.2)           91                  356   

                                                       P = 0.012             P = 0.577        P \< 0.001                            P \< 0.001                                           

  *N*-*RAS* (Failed = 26)                              Mutated               14               9                                     35.1 ± 12.4                8.0 (0.54--78.9)    9     14

  Not mutated                                          252                   234              38.2 ± 14.8                           2.5 (0.3--205.7)           115                 371   

                                                       P = 0.523             P = 0.317        P = 0.001                             P = 0.132                                            

  *WT*-*1* (Failed = 20)                               Mutated               15               9                                     35.9 ± 16.0                2.7 (0.6--72.0)     9     15

  Not mutated                                          251                   240              38.3 ± 14.6                           2.7 (0.3--205.7)           122                 369   

                                                       P = 0.403             P = 0.440        P = 0.832                             P = 0.148                                            

  EMG (Failed = 57)[a](#tf0005){ref-type="table-fn"}   Mutated               23               12                                    40.1 ± 15.5                2.4 (0.8--58.4)     11    24

  Not mutated                                          222                   221              37.9 ± 14.5                           2.8 (0.3--205.7)           112                 331   

                                                       P = 0.081             P = 0.395        P = 0.866                             P = 0.425                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

WBC, white blood cell; BM, bone marrow; and no., number.

"Failed" refers to the samples without detection results due to quality problems.

EMG refers to a group of epigenetic modifier genes investigated in this work.

One patient with *IDH1* mutation but failed in *TET2* analysis was considered as EMG mutated.

Failed number: *MLL* fusion gene/PKD mutations (n = 1), *DNMT3A* (n = 13), *IDH1* (n = 26), *IDH2* (n = 24), *ASXL1*(n = 31), and *TET2* (n = 27).

###### 

The relationship between Sanz risk stratification or gene mutational status and CR rate.

                               Training group   Validation group                                          
  ---------------------------- ---------------- ---------------------------------------- ---------------- ----------------------------------------
  Sanz risk stratification                                                                                
   High                        52/57 (91.2)     0.007[a](#tf0010){ref-type="table-fn"}   65/74 (87.8)     0.007[a](#tf0010){ref-type="table-fn"}
   Intermediate                121/131 (92.3)                                            110/117 (94.0)   
   Low                         78/78 (100)                                               78/78 (100)      
  *FLT3*-ITD or -TKD                                                                                      
   Mutated                     32/34 (94.1)     0.697                                    47/50 (94.0)     1.000
   Not mutated                 219/232 (94.4)                                            202/215 (94.0)   
  *N*-*RAS*                                                                                               
   Mutated                     13/14 (92.9)     0.552                                    9/9 (100)        1.000
   Not mutated                 231/244 (94.7)                                            227/242 (93.8)   
  *WT1*                                                                                                   
   Mutated                     9/11 (81.8)      0.136                                    11/13 (84.6)     0.179
   Not mutated                 225/238 (94.5)                                            239/253 (94.5)   
  EMG                                                                                                     
   Mutated                     13/14 (92.9)     0.217                                    19/21 (90.5)     0.068
   Not mutated                 221/224 (98.7)                                            205/209 (98.1)   
  Double or triple mutations                                                                              
   Yes                         8/9 (88.9)       0.412                                    8/9 (88.9)       0.429
   No                          243/257 (94.6)                                            245/260 (94.2)   

Low risk vs. intermediate-risk or high-risk.

###### 

The estimated 5 year OS and DFS rates in different clinical and gene mutation groups.

                               Estimated 5 year OS rate (%)     Estimated 5 year DFS rate (%)
  ---------------------------- -------------------------------- ---------------------------------
  Sanz risk stratification                                      
   High                        80.5 ± 3.8                       87.8 ± 3.4
   Intermediate                89.1 ± 2.2                       93.4 ± 1.9
   Low                         99.2 ± 0.8                       96.3 ± 1.7
   P, HR (95% CI)              \< 0.001, 0.355 (0.229--0.550)   0.022, 0.554 (0.335--0.919)
  *FLT3*                                                        
   Mutated                     89.9 ± 1.6                       89.1 ± 4.0
   Not mutated                 89.4 ± 3.6                       93.6 ± 1.4
   P, HR (95% CI)              0.818, 1.093 (0.512--2.336)      0.188, 1.765 (0.757--4.115)
  *WT*-*1*                                                      
   Mutated                     83.3 ± 7.6                       NA\*
   Not mutated                 89.7 ± 1.5                       92.2 ± 1.4
   P, HR (95% CI)              0.241, 1.845 (0.663--5.135)      0.422, 0.046 (0.000--84.431)
  *N*-*RAS*                                                     
   Mutated                     87.0 ± 9.1                       85.9 ± 9.5
   Not mutated                 90.2 ± 1.5                       93.3 ± 1.3
   P, HR (95% CI)              0.954, 0.959 (0.232--3.958)      0.617, 1.443 (0.343--6.069)
  EMGs                                                          
   Mutated                     74.3 ± 8.0                       76.7 ± 7.8
   Not mutated                 90.2 ± 1.6                       93.9 ± 1.4
   P, HR (95% CI)              0.008, 2.797 (1.305--5.998)      \< 0.001, 5.238 (2.225--12.332)
  Double or triple mutations                                    
   Yes                         68.8 ± 11.7                      78.3 ± 11.1
   No                          90.6 ± 1.4                       93.4 ± 1.3
   P, HR (95% CI)              0.008, 3.471 (1.374--8.763)      0.035, 3.6000 (1.092--11.872)

NA, not available \*no relapse due to small sample size.

###### 

Multivariate analysis of clinical and molecular variables for CR, OS and DFS in the pooled group.

  ----------------------------------------------------------------------------------------------------------------------
  Variables                    CR      OS                     DFS                                 
  ---------------------------- ------- ---------------------- ---------- ---------------- ------- ----------------------
  Age                          NS      --                     NS         --               NS      --

  WBC count                    NS      --                     NS         --               NS      --

  *FLT3* mutations             NS      --                     NS         --               NS      --

  *WT1* mutations              0.048   0.297 (0.089--0.988)   NS         --               NS      --

  *N*-*RAS* mutation           NS      --                     NS         --               NS      --

  EMG mutations                NS      --                     0.015      2.721\           0.001   4.702\
                                                                         (1.212--6.105)           (1.895--11.671)

  Double or triple mutations   NS      --                     NS         --               NS      --

  Sanz risk stratification     0.001   2.815\                 \< 0.001   0.386\           0.09    0.638 (0.380--1.072)
                                       (1.566--5.059)                    (0.247--0.605)           
  ----------------------------------------------------------------------------------------------------------------------

[^1]: Contributed equally.
